1. Insulin use in type II diabetic patients: a predictive of mortality in covid-19 infection
- Author
-
Marc Assaad, Nakisa Hekmat-Joo, Jeff Hosry, Ali Kassem, Ahmad Itani, Loai Dahabra, Ahmad Abou Yassine, Julie Zaidan, and Dany El Sayegh
- Subjects
Covid-19 ,SARS-CoV-2 ,Coronavirus ,Type II Diabetes mellitus ,Insulin Resistance ,Insulin ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Introduction Starting December 2019, the world has been devastated by the rapid spread of coronavirus disease 2019 (Covid-19). Many risk factors have been associated with worse outcomes and death from Covid-19 pneumonia including having diabetes mellitus. To date, it is not clear if all group of diabetics share the same risk of complications with COVID-19 infection. This study aims to compare disease severity and mortality rate in insulin users versus non-insulin users. Methods In this retrospective case–control study conducted at the largest health care network in New York state, we included adult, diabetic patients admitted from March 2020 to October 2020 with Covid-19 pneumonia. We compared the baseline characteristics in addition to outcomes of diabetic patients on home insulin (cases) and non-insulin user diabetics (controls). In addition, to determine if home insulin use is associated with an increased mortality, we conducted a cox regression analysis. Results We included 696 patients in the study period with a median age of 57 years, interquartile range [IQR] 51–62, and median body mass index 29.9 (IQR: 26–34.7). The majority (476 [68%]) were males. We identified 227 cases (33%) and 469 controls (67%). More cases than controls were hypertensive (74% vs 67%, p = 0.03), on ACE/ARB (50% vs 42%, p = 0.05), and had a hemoglobin A1c > 8.1 (71% vs 44%, p
- Published
- 2022
- Full Text
- View/download PDF